IDO1 and familial pancreatic carcinoma: Carbidopa, an FDA-approved drug for Parkinson’s disease, acts as an AHR agonist, impeding the growth of pancreatic cancer cells by inhibiting IDO1 (indoleamine 2,3-dioxygenase-1) [170].